Drugs Information:
Niraparib
Basic Information
|
||
ID | DDInter1297 | |
Drug Type | small molecule | |
Molecular Formula | C19H20N4O | |
Molecular Weight | 320.396 | |
CAS Number | 1038915-60-4 | |
Description | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.[L43277] Niraparib is selective towards PARP-1 and PARP-2.[A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.[L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019.[L43747] | |
ATC Classification | L01XK02 | |
IUPAC Name | 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide | |
InChI | PCHKPVIQAHNQLW-CQSZACIVSA-N | |
Canonical SMILES | NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1 | |
Useful Links | DrugBank ChEBI PubChem Substance ChemSpider BindingDB PharmGKB Wikipedia ChEMBL ZINC |
Interactions with
Niraparib
Filter:
Severity level | ID | Name | Mechanism | Detail |
---|
Interactions with diseases
Filter:
Severity level | Disease name | Text | References |
---|
Interactions with foods
Filter:
Severity level | Food name | Description | Management | Mechanism | References |
---|
Interactions with compound preparation
Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
---|